● In Stock
PT-141
≥99% Purity | HPLC Verified
$45.00
PASSED
Sterility & Endotoxins
PASSED
Net Content & Purity
Purity:
≥99%
Store at
-20°C
FDA-approved melanocortin agonist (Vyleesi) studied for hypoactive sexual desire disorder. Research use only.
Research Use OnlyNot for human or veterinary use. For in vitro laboratory research only.
| Strength | 10mg |
| molecular_formula | C50H68N14O10 |
| Molecular Weight | 1025.18 g/mol |
| Purity | >99% (HPLC) |
| Form | Lyophilized Powder |
100+
Published Studies
Melanocortin receptor research
7
Amino Acids
Cyclic heptapeptide structure
2019
FDA Approval (Vyleesi)
Approved for HSDD in premenopausal women
99%+
Purity Verified
HPLC tested, COA included
How PT-141 Works
Melanocortin receptor agonism studied in preclinical and clinical research
MC4R Agonism
Melanocortin-4 Receptor Activation
PT-141 (bremelanotide) acts as a non-selective melanocortin receptor agonist with high affinity for MC3R and MC4R. Activation of MC4R in the central nervous system is associated with the compound's observed effects on arousal pathways in preclinical and clinical research.
- High-affinity binding at MC3R and MC4R
- Central nervous system activity via hypothalamic pathways
- Distinct mechanism from PDE5 inhibitors (no vascular action)
Central Pathways
Hypothalamic Signaling Modulation
Research demonstrates PT-141 acts centrally through hypothalamic and limbic system circuits, influencing dopaminergic and serotonergic pathways. This central mechanism of action distinguishes it from peripherally-acting compounds and is the basis for its FDA-approved clinical indication.
- Modulates dopaminergic neurotransmission
- Acts on hypothalamic arousal circuits
- Distinct from peripheral vascular mechanisms
Alpha-MSH Analog
Cyclic MSH Derivative
PT-141 is a synthetic cyclic analog of alpha-melanocyte stimulating hormone (α-MSH). Its cyclic structure confers metabolic stability and improved receptor selectivity compared to its linear precursor. The compound is derived from Melanotan II via hydrolysis of the cyclic lactam ring.
- Cyclic structure enhances metabolic stability
- Derived from Melanotan II via chemical modification
- Improved selectivity profile vs. linear α-MSH
What Research Has Shown
Key findings from clinical and preclinical publications
⚠️ RESEARCH NOTE
PT-141 (bremelanotide) is FDA-approved as Vyleesi for HSDD in premenopausal women. Research-grade PT-141 available here is for in vitro research use only and is not intended to replicate or substitute for the approved pharmaceutical product. Data references clinical trial findings for informational purposes.
Research Applications
Primary areas of investigation for melanocortin receptor agonists
Sexual Dysfunction
HSDD Research
Clinical trials demonstrated significant improvement in satisfying sexual events and desire scores in women with hypoactive sexual desire disorder. Basis for FDA approval as Vyleesi in 2019.
Receptor Pharmacology
Melanocortin System
Research into MC3R and MC4R signaling cascades, including downstream cAMP production and modulation of hypothalamic neuropeptide systems involved in energy homeostasis and arousal.
Erectile Dysfunction
Male Sexual Function
Early clinical research explored PT-141's potential in male subjects, with Phase II trials showing dose-dependent erectile responses mediated through central MC4R pathways independent of the NO/cGMP cascade.
Neuropharmacology
CNS Mechanism Studies
Investigation of central nervous system melanocortin receptor distribution, downstream signaling via Gs-coupled cAMP pathways, and interaction with dopaminergic reward circuitry in preclinical models.
Safety Profile from Research
Clinical and preclinical safety data
✓FDA-approved safety data available from Phase III clinical trials of bremelanotide (Vyleesi); most common adverse events were nausea, flushing, and injection site reactions.
✓Transient blood pressure changes observed in Phase III trials; contraindicated in subjects with cardiovascular risk per FDA labeling.
✓No significant organ toxicity observed in preclinical studies at research-relevant concentrations.
✓Short half-life (~2.7 hours) limits systemic exposure duration in research models.
⚠️ Research-grade PT-141 is for in vitro research use only. It is not the FDA-approved Vyleesi formulation and is not intended for human therapeutic use.
Compound Information
Technical specifications
| Chemical Name | Bremelanotide |
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Molecular Weight | 1025.18 Da |
| Molecular Formula | C₅₀H₆₈N₁₄O₁₀ |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage (lyophilized) | -20°C for long-term stability |
| Storage (reconstituted) | 2–8°C, use within 30 days |
| Solubility | Water or bacteriostatic water |
| COA | Included with every order |
Frequently Asked Questions
Common questions about PT-141 / Bremelanotide
PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide and analog of alpha-melanocyte stimulating hormone (α-MSH). It acts as an agonist at melanocortin receptors, particularly MC3R and MC4R. The compound was developed from Melanotan II and later approved by the FDA as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
PT-141 has a fundamentally different mechanism than PDE5 inhibitors (like Viagra/Cialis). PDE5 inhibitors work peripherally by increasing blood flow via the nitric oxide/cGMP pathway. PT-141 acts centrally through melanocortin receptors in the brain's hypothalamic and limbic circuits, modulating dopaminergic neurotransmission associated with arousal and desire — not vascular engorgement.
Bremelanotide (the pharmaceutical formulation, Vyleesi) is FDA-approved as of June 2019 for treating HSDD in premenopausal women. Research-grade PT-141 sold here is not the approved pharmaceutical formulation and is intended solely for in vitro research purposes. It should not be used therapeutically.
PT-141 binds to multiple melanocortin receptor subtypes. It has highest affinity for MC4R and MC3R, with lower affinity for MC1R, MC2R, and MC5R. MC4R activation in the hypothalamus is believed to be the primary driver of its effects on arousal-related circuits based on receptor knockout studies and pharmacological profiling research.
Phase III trials (RECONNECT studies) enrolled premenopausal women with HSDD. Treatment showed a statistically significant increase in satisfying sexual events per month and significant improvement in distress scores (FSDS-DAO) compared to placebo. The most common adverse events were nausea (40%), flushing (20%), and headache (11%).
Lyophilized PT-141 should be stored at -20°C for long-term stability and protected from light. Once reconstituted in bacteriostatic water or sterile water, store at 2–8°C and use within 30 days. Avoid repeated freeze-thaw cycles, which can degrade peptide integrity.
Sources & References
PubMed
Bremelanotide for Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
2019
PubMed
Melanocortin Receptors and Erection in Men and Animals: Pharmacological Properties and Clinical Applications
2003
PubMed
Melanocortin Peptide Therapeutics: Historical Milestones, Clinical Studies and Commercialization
2006
Published research on this compound is available through PubMed and other scientific databases.
Certificate of Analysis
| Analysis Date: | Available on request |
| Lot Number: | Batch-specific |
| Purity: | >99% (HPLC) |
Third-Party Testing
- ✓ Identity verification (Mass Spectrometry)
- ✓ Purity analysis (HPLC)
- ✓ Sterility testing
- ✓ Endotoxin screening
Storage Conditions
- Lyophilized: Store at -20°C, protected from light
- Reconstituted: Store at 2-8°C, use within 30 days
- Stability: 24 months from manufacture date when stored properly
Handling Guidelines
- Use sterile technique when reconstituting
- Allow vial to reach room temperature before opening
- Reconstitute with bacteriostatic water or sterile saline
- Avoid repeated freeze-thaw cycles
RESEARCH INSIGHTS
3D Structure
PT-141
This compound has been extensively studied in peer-reviewed literature. Eon Peptides provides this product exclusively for legitimate in-vitro research and analytical applications.
- • High-purity research compound
- • Full analytical documentation included
- • Third-party verification available
PRODUCT SPECIFICATIONS
LOT DATA
| Lot Number | Assigned on shipment |
| Verified Purity | >99% |
| Quantity | 5mg |
MOLECULAR DATA
| Molecular Formula | Available on request |
| Form | Lyophilized Powder |
| Appearance | White to off-white powder |
Researchers who studied this also studied...
Related products
-
Price range: $85.00 through $260.00 Select options This product has multiple variants. The options may be chosen on the product page
